glucocorticoid osteoporosis; osteoporotic fracture; bisphosphonates; FRAX algorithm
https://doi.org/10.14412/1996-7012-2013-2436
Abstract
Glucocorticoids (GC) are extensively used to treat patients with systemic rheumatic diseases, which can improve their quality of life and substantially increase its span. At the same time their use is associated with the development of serious adverse reactions that cannot be always avoided. One of such complications is osteoporosis (OP) that gives rise to an increased risk for fractures. The paper gives recent clinical guidelines for the treatment and prevention of GC OP and the specific features of management in patients in relation to their age.
About the Authors
Natalia Vladimirovna Toroptsova
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
I A Baranova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
References
1. <div><p>Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol. 1996;14(2):199–206.</p><p>Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001;27(1):131–6. DOI: http://dx.doi.org/10.1016%2FS0889-857X%2805%2970196-4.</p><p>Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoids-induced osteoporosis. Endocrinology. 1999;140(10):4382–9. DOI: http://dx.doi.org/10.1210%2Fen.140.10.4382.</p><p>Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–9. DOI: http://dx.doi.org/10.1359%2FJBMR.040134.</p><p>Diez-Perez A, Hooven FH, Adachi JD et al. Regional differences in</p><p>treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49(3):493–8. DOI: 10.1016/j.bone.2011.05.007. Epub 2011 May 14.</p><p>Van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol Phys Med. 2000;39(12):1383–9.</p><p>Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other</p><p>predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–9. DOI: http://dx.doi.org/10.1002%2Fart.11283.</p><p>Kanis JA, Johansson H, Oden A, McCloskey E. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–16. DOI: http://dx.doi.org/10.1007%2Fs00198-010-1524-7.</p><p>Compston J, Reid DM, Boisdron J et al. Group for the Respect of Ethics and Excellence in Science Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int. 2008;19(9):1247–50. DOI: http://dx.doi.org/10.1007%2Fs00198-008-0670-7.</p><p>Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809–22. DOI: http://dx.doi.org/10.1056%2FNEJMoa067312.</p><p>Reid DM, Devogelaer JP, Saag K et al. HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253–63.</p><p>Лесняк ОМ, Баранова ИА, Торопцова НВ. Клинические рекомендации: Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше. Москва: Литера; 2013. 48 с. [Lesnyak OM, Baranova IA, Toroptsova NV. Klinicheskie rekomendatsii: Diagnostika, profilaktika i lechenie glyukokortikoidnogo osteoporoza u muzhchin i zhenshchin 18 let i starshe. Moscow: Litera; 2013. 48 p.]</p></div><br />
Review
For citations:
Toroptsova NV, Baranova IA. glucocorticoid osteoporosis; osteoporotic fracture; bisphosphonates; FRAX algorithm. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2013;7(4):33-37. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2436
Views:
1380
Email this article 